Adaptive COVID-19 Treatment Trial (ACTT) – Study Results – ClinicalTrials.gov
Adaptive COVID-19 Treatment Trial (ACTT) – Study Results.
Related Articles
RAS/RAFlandscape in monoclonal plasma cell conditions.
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma
Key Points. Quantification of the primary myeloma cell surface proteome enables unbiased discovery of novel therapeutic targets.Targeting SEMA4A using an a
Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma
Amplification of chromosome 1q (chr1q-amp) is an adverse prognostic feature in multiple myeloma (MM). In this Plenary paper, Trasanidis and colleagues perf
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19 | mBio
As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma…
Survival in Patients With Hematologic Cancers and COVID-19
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Safety of COVID‐19 convalescent plasma: A definitive systematic review and meta‐analysis of randomized controlled trials
Click on the article title to read more.
A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA… by Carsten Müller-Tidow
EHA Library; Müller-Tidow C. Jun 10 2022; 357146;
Early Outpatient Treatment for Covid-19 with Convalescent Plasma | NEJM
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent Plasma
COVID-19 vaccination and breakthrough infections in patients with cancer
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of…
The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19
Background Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a…